Sanofi-aventis Initiates Phase III Study With Teriflunomide As Adjunct Therapy With Interferon Beta To Further Explore Clinical Benefits In Multiple Sclerosis
PARIS, October 26, 2010 /PRNewswire/ -- Sanofi-aventis announced today the initiation of a multinational Phase III study evaluating the efficacy and safety of two doses of once daily teriflunomide…